A threesome on drugs: talking $BMYRT with Matt and Dan
About this episode
Matt Turk and Dan Schneeberger do an extremely deep dive into BMYRT. BMYRT is a contingent value right (CVR) established when Bristol-Myers Squibb (BMY) bought Celgene. While CVR's are extremely risky and there is a real chance of this proving worthless, Matt and Dan walk through what a CVR is, why a CVR might be overlooked, and why they think the odds of approval for the drugs underlying BMY's CVR are much higher than the market suggests.
Again, CVRs are risky, and nothing in this podcast is investing advice.
Twitter handles:
Matt: Given2Tweet (https://twitter.com/given2tweet)
Dan: Sheep of Wall Street (https://twitter.com/Biohazard3737)
Get every episode summarized
Each time Yet Another Value Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Yet Another Value Podcast
UK stocks are dirt cheap. Why won't the boards act? $ZIG $CRW | Undervalued-Shar...
Yet Another Value Podcast
Zack Buckley on $PRTH's take private
Yet Another Value Podcast
$TBBB: Tiendas 3B is Mexico's Aldi. Is it too late to buy? | Fruit Tree Capital
Yet Another Value Podcast
$LMB: Limbach missed the data center boom. Is that the opportunity? | 1 Main Cap...
Yet Another Value Podcast